RAC1 and Netherton syndrome: Any future in vitro or animal studies examining the potential therapeutic benefits of Rac1 inhibition in reducing the acute-onset proteinuria observed in NS must be careful to ensure robust toxicology screening is performed, although the possibility of anti-proteinuria medication targeted at reducing disease-associated podocyte hypermotility is an intriguing possibility.